Illustrations represent an EASI-75 response. See DUPIXENT clinical study responses. Individual patient responses may vary.

Consider DUPIXENT for Your Adult Patients With Uncontrolled Moderate-to-Severe Atopic Dermatitis

You may have adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable. DUPIXENT may be an appropriate choice for these patients who are struggling to control their disease on prescription topical therapies. DUPIXENT can be used with or without topical corticosteroids.1

 

See below for examples of patients who might be appropriate for DUPIXENT.

Meet Carla:
Constantly Covering Up

The lesions on my face and hands are the worst.
Sometimes it’s hard to remember what it was
like without lesions.

—26-year-old teacher

Worried about her visible lesions

  • Worried about her appearance because of lesions located on her face and hands
  • Feels obligated to explain to her students and their parents that her lesions are not contagious

Her atopic dermatitis remains uncontrolled despite being on regimens of topical corticosteroids and topical calcineurin inhibitors

  • Not adequately controlled despite having used a variety of topical prescription therapies
  • Uses emollients for moisturizing and topical corticosteroids several times a day
  • Given oral corticosteroids 3 times last year for her severe flares

She is constantly concerned about the extent and severity of her lesions

  • Diagnosed 15 years ago
  • Suffers from uncontrolled disease, with more than 20% of her body covered in lesions

Not actual patient. For illustrative purposes only.

Meet Issac:
Intense, Persistent Itch

Nearly every day, I find myself dealing with intense itch.

—37-year-old salesperson

Wants a treatment that works for him

  • Reports intense pruritus
  • Running out of options to treat lesions and itch despite following countless doctors’ instructions
  • Frustrated after visiting multiple doctors and trying different treatments

His atopic dermatitis remains uncontrolled despite use of topical corticosteroids

  • Inadequate control of his pruritus during the day and at night
  • Uses antihistamines to help with pruritus at night
  • Bathes with emulsifying oils and applies an emollient immediately after

Suffering from atopic dermatitis with intense itching

  • Battling his disease for over 20 years
  • Has 35% of his body covered in lesions

Not actual patient. For illustrative purposes only.

Meet Tina:
Treated With Steroids and Still
Uncontrolled

I follow my regimen of creams, but I'm
always wondering if it's ever going to work.

—43-year-old nurse

Longing for help with her uncontrolled disease

  • Has tried a variety of topical prescription therapies and is frustrated with the lack of results
  • Concerned her patients are hesitant to receive care from her during visible flares
  • Required to be on her feet several hours a day

Her atopic dermatitis remains uncontrolled despite treatment

  • Frequently washes her hands at work, which dries out her skin and causes exacerbations
  • Was prescribed oral corticosteroids and intramuscular corticosteroid shots after experiencing intense flares
  • Has to use a humidifier to add moisture inside her home
  • Has tried phototherapy but chose not to continue it

Frustrated with the lack of control over the past 12 months despite current regimen of topical therapies

  • Suffering from the disease for the past 15 years
  • Family history of atopy
  • Has not been able to control her disease despite her treatments and efforts to avoid potential triggers

Not actual patient. For illustrative purposes only.

Measuring the signs and symptoms of atopic dermatitis

The following scales are important measures used for assessing the severity of atopic dermatitis. The Investigator’s Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Pruritus Numerical Rating Scale (NRS) are all helpful tools that focus on the signs and symptoms of atopic dermatitis.2-5

IGA scores the overall severity of the clinical signs of atopic dermatitis

A 0- to 4-point scoring system that reflects the physician’s overall assessment (whole body area average) of the severity of skin lesions in atopic dermatitis. The scoring focuses on signs of erythema and papulation/infiltration to detect the level of severity.2

4Severe Disease
Severe erythema and severe papulation/infiltration
3Moderate Disease
Moderate erythema and moderate papulation/infiltration
2Mild Disease
Mild erythema and mild papulation/infiltration
1Almost Clear
Just perceptible erythrema, and just perceptible papulation/infiltration
0Clear
No inflammatory signs of dermatitis

EASI grades the severity of the signs of eczema and the extent to which the patient is affected3

The severity of each eczema sign is assessed in the chosen body region on a scale of 0 to 3.4

The severity of each eczema sign is assessed in the chosen body region on a scale of 0 to 3.4 The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6. Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more, while head and neck are weighted the least.3,4
Each region gets a total region score: Severity score x Area score x Multiplier = Region score The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.3,4

The EASI scale is specific to atopic dermatitis and is generally not comparable to other scales measuring lesion area and severity in other disease states.6

Pruritus NRS assesses the maximum itch intensity over the previous 24 hours

A patient-reported measure that uses a 0- to 10-point scale, in which patients are asked5:

On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?

None The Worst
Imaginable
Getting Started Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Frequently Asked
Questions
Have questions? Get answers to some of
the most commonly asked questions.
Get Answers
DUPIXENT MyWay Get information about DUPIXENT
MyWay
, a program with personalized
nursing and coverage support.
Explore Resources
Reference:
References:
  1. DUPIXENT Prescribing Information. March 2017.
  2. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  3. Data on file, Regeneron Pharmaceuticals, Inc.
  4. DUPIXENT Prescribing Information. March 2017.
  5. Data on file, Regeneron Pharmaceuticals, Inc.
  6. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  7. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354.
  8. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):1-25. doi:10.4172/2155-9899:100011
  9. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324-336.
  10. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(6):1420-1432.
  11. Guttman-Yassky E, Dhingra N, Leung DY. New era of biological therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13(4):549-561.
  12. Data on file, Regeneron Pharmaceuticals, Inc.
  13. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  14. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357.
  15. DUPIXENT Prescribing Information. March 2017.
  16. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [published May 4, 2017]. Lancet. 2017;389(10086):2287-2303.
  17. DUPIXENT Prescribing Information. March 2017.
  18. Data on file, Regeneron Pharmaceuticals, Inc.
  19. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  20. DUPIXENT Prescribing Information. March 2017.
  21. Data on file, Regeneron Pharmaceuticals, Inc.
  22. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  23. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.
  24. DUPIXENT Prescribing Information. March 2017.
  25. Data on file, Regeneron Pharmaceuticals, Inc.
  26. DUPIXENT Prescribing Information. March 2017.
  27. Data on file, Regeneron Pharmaceuticals, Inc.
  28. DUPIXENT Prescribing Information. March 2017.
  29. Data on file, Regeneron Pharmaceuticals, Inc.
  30. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357.
  31. EASI User Guide. HOME—Harmonising Outcome Measures for Eczema website. http://www.homeforeczema.org/documents/easi-user-guide-jan-2017-v3.pdf. Accessed January 11, 2017.
  32. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.
  33. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11-18.
  34. DUPIXENT Prescribing Information. March 2017.
  35. Data on file, Regeneron Pharmaceuticals, Inc.
  36. Torrelo A, Ortiz J, Alomar A, Ros S, Pedrosa E, Cuervo J. Health-related quality of life, patient satisfaction, and adherence to treatment in patients with moderate or severe atopic dermatitis on maintenance therapy: the CONDA-SAT study. Actas Dermosifiliogr. 2013;104(5):409-417.
  37. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  38. DUPIXENT Prescribing Information. March 2017.